Reply to Dr. Chandrasekar (Clin Infect Dis 2001; 32:320-1) and Drs. Marr and Boeckh (Clin Infect Dis 2001; 32:321)
Open Access
- 1 February 2001
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (3) , 518-519
- https://doi.org/10.1086/318517
Abstract
Sir—The point raised by Dr. Chandrasekar [1] regarding treatment with fluconazole is appropriate, and we thank him for reminding us about the 1997 guidelines frKeywords
This publication has 9 references indexed in Scilit:
- Practice Guidelines for Fungal Infections: A Risk-Guided ApproachClinical Infectious Diseases, 2001
- Empirical Antifungal Therapy for Persistent Fever in Patients with NeutropeniaClinical Infectious Diseases, 2001
- Practice Guidelines for Diseases Caused by AspergillusClinical Infectious Diseases, 2000
- Practice Guidelines for the Treatment of CandidiasisClinical Infectious Diseases, 2000
- A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancerThe American Journal of Medicine, 2000
- A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropeniaThe American Journal of Medicine, 1998
- 1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained FeverClinical Infectious Diseases, 1997
- Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trialEuropean Journal Of Cancer, 1996
- Editorial Response: Evolving Risk Factors for Invasive Fungal Infections--All Neutropenic Patients Are Not the SameClinical Infectious Diseases, 1994